@article{4496cf604b2d443d82f840a1951616f2,
title = "American Radium Society Appropriate Use Criteria on Radiation Therapy for Extensive-Stage SCLC",
abstract = "Introduction: The standard-of-care therapy for extensive-stage SCLC has recently changed with the results of two large randomized trials revealing improved survival with the addition of immunotherapy to first-line platinum or etoposide chemotherapy. This has led to a lack of clarity around the role of consolidative thoracic radiation and prophylactic cranial irradiation in the setting of chemoimmunotherapy. Methods: The American Radium Society Appropriate Use Criteria are evidence-based guidelines for specific clinical conditions that are reviewed by a multidisciplinary expert panel. The guidelines include a review and analysis of current evidence with the application of consensus methodology (modified Delphi) to rate the appropriateness of treatments recommended by the panel for extensive-stage SCLC. Results: Current evidence supports either prophylactic cranial irradiation or surveillance with magnetic resonance imaging every 3 months for patients without evidence of brain metastases. Patients with brain metastases should receive whole-brain radiation with a recommended dose of 30 Gy in 10 fractions. Consolidative thoracic radiation can be considered in selected cases with the recommended dose ranging from 30 to 54 Gy; this recommendation was driven by expert opinion owing to the limited strength of evidence, as clinical trials addressing this question remain ongoing. Conclusions: Radiation therapy remains an integral component in the treatment paradigm for ES-SCLC.",
keywords = "Appropriateness criteria, Extensive stage, Prophylactic cranial irradiation, Small cell lung cancer, Thoracic radiation",
author = "{Expert Panel Thoracic Malignancies:} and Higgins, {Kristin A.} and Simone, {Charles B.} and Arya Amini and Chetty, {Indrin J.} and Jessica Donington and Edelman, {Martin J.} and Chun, {Stephen G.} and Kestin, {Larry L.} and Benjamin Movsas and Rodrigues, {George B.} and Rosenzweig, {Kenneth E.} and Slotman, {Ben J.} and Rybkin, {Igor I.} and Andrea Wolf and Chang, {Joe Y.}",
note = "Funding Information: The authors thank Ms. Andrea Taylor and the Appropriate Use Criteria Steering Committee for assistance in the generation of this document. Disclosure: Dr. Chun reports receiving consulting/traveling fees from AstraZeneca PLC. Dr. Simone II reports receiving consulting fees from Varian Medical Systems Inc. Dr. Amini reports receiving consulting/speaker's bureau fees from AstraZeneca PLC and consulting fees from RefleXion Medical Inc. Dr. Edelman reports receiving consulting fees from WindMIL Therapeutics Inc., Merck, Precision Oncology, Syndax Pharmaceuticals Inc., GlaxoSmithKline PLC, and AstraZeneca PLC; personal honorarium from Takeda Pharmaceutical Company Inc., and Andarix Pharmaceuticals Inc.; and consulting fees and stock options from BioMarker Strategies LLC. Dr. Higgins reports receiving consulting/advisory board fees from AstraZeneca PLC; advisory board fees from Genentech Inc.; and funded research from RefleXion Medical Inc. Dr. Movsas reports receiving fees from ViewRay Inc., Varian Medical Systems Inc., and Philips NV. Dr. Slotman reports receiving fees from ViewRay Inc. and Varian Medical Systems Inc. Dr. Chang reports receiving fees from Bristol-Myers Squibb, MD Anderson Cancer Center, consulting/advisory board fees from AstraZeneca PLC, Varian Medical Systems Inc., and Global Oncology One Inc. The remaining authors declare no conflict of interest. Publisher Copyright: {\textcopyright} 2020",
year = "2021",
month = jan,
doi = "10.1016/j.jtho.2020.09.013",
language = "English (US)",
volume = "16",
pages = "54--65",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "1",
}